← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › VIRAL VACCINES › Rubella vaccines
rubella, combinations with mumps, live attenuated
J07BJ51
Forms & Strengths
- Lyophilized suspension for subcutaneous injection
- Combination live attenuated mumps and rubella vaccine (or MMR containing measles)
Adult Dosing
- 0.5 mL subcutaneously as a single dose
- Second dose administered if indicated for lack of evidence of immunity
Pediatric Dosing
- 0.5 mL subcutaneously for children aged 12 to 15 months
- Second dose typically administered at 4 to 6 years of age
Indications
- Active immunization against rubella and mumps infections
- Prevention of congenital rubella syndrome
Mechanism of Action
- Induces active immunity by replication of live attenuated strains of rubella and mumps viruses
- Stimulates humoral and cell-mediated immune responses without causing active clinical disease
Contraindications
- Severe allergic reaction to any component of the vaccine, including neomycin or gelatin
- Primary or acquired immunodeficiency states
- Pregnancy
- Moderate to severe acute illness
Adverse Reactions
- Injection site reactions (pain, erythema, swelling)
- Low-grade fever
- Transient lymphadenopathy
- Transient arthralgia and arthritis, particularly in adult women
- Parotitis
Drug Interactions
- Immunosuppressive therapies may diminish the immune response to the vaccine
- Blood products and immune globulins can interfere with the replication of live vaccine viruses and should be separated by several months
Curated Content: Needs Vetting Before Put to Clinical Use